OPKHealthcare · Diagnostics & ResearchThe 6 Wall Street analysts covering OPKO Health, Inc. hold a median 12-month price target of $3 — +69.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 4 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores OPKO Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (90): Sales and profits are climbing, and climbing faster than before.
Value (30): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on OPK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +69.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Oct 2026 | Barrington Research | Upgrade | Outperform | — |
| 16 Oct 2026 | Piper Sandler | Reiterates | Overweight | $3.00 → $4.00 |
| 29 Apr 2026 | Barrington Research | Downgrade | Market Perform | — |
| 29 Apr 2026 | Barrington Research | Downgrade | Market Perform | — |
| 2 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 20 Nov 2025 | JP Morgan | Initiates | Neutral | — |
| 31 Oct 2025 | Jefferies | Downgrade | Hold | — |
| 30 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 1 May 2025 | Barrington Research | Maintains | Outperform | — |
| 25 Apr 2025 | JP Morgan | Initiates | Neutral | — |
| 7 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Mar 2025 | Barrington Research | Maintains | Outperform | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Feb 2025 | Barrington Research | Maintains | Outperform | — |
| 8 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Nov 2024 | Barrington Research | Maintains | Outperform | — |
| 26 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Sept 2024 | Barrington Research | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OPK appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, OPKO Health, Inc. returned +27.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 49% of US stocks
Cheaper than 67% of US stocks
Cheaper than 89% of US stocks
Higher than 38% of US stocks
Higher than 42% of US stocks
Higher than 60% of US stocks
Higher than 23% of US stocks
Higher than 18% of US stocks
Higher than 39% of US stocks
Higher than 31% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OPKO Health, Inc. has a market value of $1.3B and an enterprise value of $1.4B.
Revenue in the twelve months to 30 June 2026: $587.9M. The latest quarter grew 4.3% year on year.
Net income over the same four quarters: −$72.9M, a −12.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.09.
Free cash flow in the twelve months to 30 June 2026: −$134.0M, after $10.6M of capital spending.
OPKO Health, Inc. spent $46.6M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −5.8×; forward P/E: −5.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
OPKO Health, Inc. employs 2,275 people — $258K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OPKO Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
OPKO Health reported 16% growth in third-quarter revenue from continuing operations. On its earnings call, the company outlined plans to focus on drug development and pharmaceutical products following its proposed sale of BioReference assets to Labcorp.
Why it matters — The update highlights OPKO’s revenue growth and its planned business focus after the proposed BioReference asset sale.
Seeking Alpha published a transcript of OPKO Health, Inc.’s Q3 2026 earnings call. The excerpt provides no details about the discussion.
Why it matters — The transcript is a source for OPK watchers seeking information from the company’s quarterly earnings call, but the excerpt does not disclose its contents.
OPKO Health reported a third-quarter loss of $0.05 per share, compared with the Zacks consensus estimate of a $0.07 loss. The result compares with earnings of $0.03 per share a year earlier.
Why it matters — OPK watchers may note the quarterly per-share loss was smaller than the consensus estimate, while the company reported earnings in the year-ago quarter.
OPKO Health reported third-quarter 2026 business highlights and financial results. The company said it entered into an agreement with Labcorp to sell substantially all remaining BioReference diagnostic operations.
Why it matters — The reported agreement concerns OPKO’s remaining BioReference diagnostic operations, a significant business update for investors following the company.
OPKO Health announced it will report third-quarter 2026 operating and financial results on November 4, 2026. Senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update and discuss results and financial guidance.
Why it matters — OPK watchers can use the scheduled report and management discussion to follow the company’s quarterly results and guidance.
The 6 Wall Street analysts covering OPKO Health, Inc. have a median 12-month price target of $3, with estimates ranging from $2.25 to $8.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering OPKO Health, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OPKO Health, Inc. 70 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, OPKO Health, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +69.5% from the last close, and Ticker Nerd's factor model ranks OPKO Health, Inc. 70 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OPKO Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.25 to $8.5 over the next 12 months.
OPKO Health, Inc. returned +27.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals.
The most recent item we track (MarketBeat, 5 Nov 2026): "What OPKO Health (OPK) Said on Its Q3 Earnings Call". OPKO Health reported 16% growth in third-quarter revenue from continuing operations. On its earnings call, the company outlined plans to focus on drug development and pharmaceutical products following its proposed sale of BioReference assets to Labcorp.
OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals. Through its Diagnostics segment, the company provides clinical laboratory and genetic testing services, including BioReference Health and specialized assays used in disease detection, monitoring, and patient management. Its Pharmaceutical segment markets approved therapies and supports development programs across areas such as kidney disease, hormone-related disorders, oncology, and infectious diseases. OPKO Health also works with commercial partners and maintains manufacturing, supply, and research activities across several international markets. The company plays a broad role in the healthcare market by combining testing services, marketed medicines, and pipeline assets within a single operating platform. OPKO Health, Inc. is headquartered in Miami, Florida.
CEO Dr. Phillip Frost M.D., Ph.D. · 2,275 employees · United States · https://www.opko.com
